Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Next Previous
Trial Profile

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary) ; Aripiprazole; Haloperidol; Olanzapine; Paliperidone; Perphenazine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PRIDE
  • Sponsors Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine

Most Recent Events

  • 25 Sep 2023 Results of post hoc pooled analysis of NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM) assessing the efficacy and safety of paliperidone palmitate (PP) versus oral antipsychotic (OAP) treatment in adult patients diagnosed with schizophrenia (per DSM IV or DSM 5 criteria) and varying duration of illness (o to 3 years and greater than 3 years) published in the Journal of clinical psychiatry, 2023.
  • 03 Jan 2018 Results presented in a Johnson & Johnson Media Release.
  • 03 Jan 2018 According to a Janssen Pharmaceuticals media release, the U.S. FDA approved the inclusion of real-world data from this study in the INVEGA SUSTENNA label.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top